MARKET WIREInvesting.com • 1d ago
Boundless Bio director Kevin Tang buys $51,619 in BOLD sharesInvesting.com report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
Why BOLD Stock slipped -1.22% Today — RQD Quant Desk Flash
$2.44 -1.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.43
Boundless Bio Inc. (BOLD) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $56.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BOLD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BOLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Boundless Bio Inc. (NASDAQ: BOLD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.44 (-1.22% 1D, market cap $56.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BOLD ranks #340 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BOLD compare to HRTX and RNXT in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLD carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M) and RNXT (RenovoRx Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $56.9M). Among the 5-stock peer group, BOLD leads on earnings multiple (N/A) while BOLD leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BOLD?
▼
Per BOLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782303), Boundless Bio Inc. generated $177.9M in revenue (-13.3% YoY), -$58.2M in net income, and -$47.2M in free cash flow against $157.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.43 (-0.41%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BOLD)Realized 20D OHLCV Swing Band: ±11.8%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY BOLD SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)
FRED Regime × Technicals: 67% of 52W Range • RSI-14 at 43.9 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (22% of score)
20D Institutional Volume Accumulation (±11.8% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.43+0% Next Q
38
Q2 (-2Q)Grade D$2.43-0.8% Next Q
41
Q3 (-1Q)Grade D$2.41+1.2% Next Q
43
CurrentGrade D$2.44-6.1% Hist 90D α
46
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BOLD Turnaround Squeeze
While BOLD currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.64) and Max Pain ($2.56) forces dealer call-delta covering toward $3.32.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BOLD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BOLD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BOLD Stock slipped -1.22% Today — RQD Quant Desk Flash
Boundless Bio Inc. (BOLD) slipped -1.22% to $2.44, trading at 67% of its 52-week range ($0.96 – $3.16). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 67% of its 52-week range ($0.96 – $3.16) with RSI-14 at 43.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.8% around $2.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BOLD Headlines & Catalysts
MARKET WIREStock Titan • 1d ago
10% owners buy 21,640 shares in Boundless Bio (BOLD) across three October dates.Stock Titan report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com Nigeria • 1d ago
Boundless Bio director Kevin Tang buys $25,696 of common stock By Investing.comInvesting.com Nigeria report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
At an average $2.40 per share, owners buy 10,707 shares of Boundless Bio (BOLD).Stock Titan report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 2d ago
Boundless Bio (BOLD) Edges Lower to $2.53 as Shares Hover Near Range Support - Calendar Spread Tradehttps://www.siam.in/ report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
Ten-percent owner Kevin Tang reports purchases of 149,474 Boundless Bio (BOLD) shares.Stock Titan report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BOLD)
- ✓Walkthrough of BOLD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BOLD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.41%📐 HORIZONTAL RANGE
2026-11-04O $2.47H $2.47L $2.44C $2.44VOL 91.2K
RES: $3.60SUP: $2.16SMA50: $2.64SMA200: $1.92
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BOLD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -13.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on BOLD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BOLD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BOLD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BOLD)
Health Care Rank #340 of 1015
⚔️ HRTX vs BOLD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BOLD vs. HRTX, RNXT, NMAD, CTOR)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Boundless Bio Inc. (BOLD) ranks #340 by composite RQD confidence (46/100, grade D) and #720 by equity capitalization ($56.4M). Within this direct 5-issuer industry benchmark cohort, BOLD leads on earnings valuation at N/A trailing P/E, while BOLD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BOLD currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BOLD
ACTIVE
Boundless Bio Inc. | D | 46/100 | — | — | -35.0% | -1.22% | $56.4M | Benchmark Subject |
| HRTX Heron Therapeutics Inc. | E | 34/100 | — | 73.3% | -35.0% | +6.27% | $56.0M | /hrtx-vs-bold → |
| RNXT RenovoRx Inc. | E | 29/100 | — | 70.9% | -35.0% | -5.26% | $56.9M | /rnxt-vs-bold → |
| NMAD Nomad Power Solutions Inc. | E | 31/100 | — | — | -35.0% | -2.53% | $55.9M | /nmad-vs-bold → |
| CTOR Citius Oncology Inc. | E | 34/100 | — | — | -35.0% | +7.24% | $55.2M | /ctor-vs-bold → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001782303 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Boundless Bio Inc. (BOLD) reported GAAP revenue of $177.9M (-13.3% vs. FY2024 revenue of $205.1M , and +16.0% cumulative change since FY2023) , GAAP net income of -$58.2M, operating cash flow of -$46.7M, and free cash flow of -$47.2M (+25.5% YoY). On the balance sheet, BOLD closed FY2025 with $157.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $177.9M | -$58.2M | -$46.7M | -$47.2M | $157.1M | — |
| FY2024 (FY) | 2024-12-31 | $205.1M | -$65.4M | -$60.8M | -$63.4M | $206.4M | — |
| FY2023 (FY) | 2023-12-31 | $153.4M | -$49.4M | -$46.9M | -$46.9M | — | — |
3. BOLD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BOLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Boundless Bio Inc. (NASDAQ: BOLD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.44 (-1.22% 1D, market cap $56.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BOLD ranks #340 in composite RQD confidence.
How does BOLD compare to HRTX and RNXT in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLD carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M) and RNXT (RenovoRx Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $56.9M). Among the 5-stock peer group, BOLD leads on earnings multiple (N/A) while BOLD leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BOLD?
Per BOLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782303), Boundless Bio Inc. generated $177.9M in revenue (-13.3% YoY), -$58.2M in net income, and -$47.2M in free cash flow against $157.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BOLD trading relative to its 50-day, 200-day, and 52-week technical levels?
BOLD last traded at $2.44 (-1.22% on volume of 91,159 shares), positioning the stock -7.58% below its 50-day simple moving average ($2.64) and +27.08% above its 200-day simple moving average ($1.92). Across its 52-week range of $0.96 to $3.16, BOLD sits at the 67.3% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($2.15 to $2.73).
ROARABLE RATING BRIEF • RQD 46/100 (D)
✓ SEC XBRL & RQD VERIFIED
BOLD — Boundless Bio Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Boundless Bio Inc. (BOLD) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $2.44 (-1.22% 1D, market capitalization $56.4M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (10/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (13/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Boundless Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Market capitalization is $0.1B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Boundless Bio Inc. (BOLD) reported $177.9M in annual revenue (up from $205.1M in FY2024, -13.3% YoY) and -$58.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($153.4M revenue, -$49.4M net income) through FY2025, BOLD scaled operating cash flow to -$46.7M and free cash flow to -$47.2M, backed by $157.1M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.96 – $3.16 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — Investors should note that the only sector context provided is the Health Care / Pharmaceutical Preparations classification and a beta of 1.0.
- Key Question #1: Can BOLD sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $177.9M and free cash flow of -$47.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is BOLD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
BOLD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Boundless Bio Inc. (BOLD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Investing.com • 1d ago
Boundless Bio director Kevin Tang buys $51,619 in BOLD shares Investing.com report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
10% owners buy 21,640 shares in Boundless Bio (BOLD) across three October dates. Stock Titan report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Nigeria • 1d ago
Boundless Bio director Kevin Tang buys $25,696 of common stock By Investing.com Investing.com Nigeria report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
At an average $2.40 per share, owners buy 10,707 shares of Boundless Bio (BOLD). Stock Titan report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 2d ago
Boundless Bio (BOLD) Edges Lower to $2.53 as Shares Hover Near Range Support - Calendar Spread Trade https://www.siam.in/ report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
Ten-percent owner Kevin Tang reports purchases of 149,474 Boundless Bio (BOLD) shares. Stock Titan report covering Boundless Bio Inc. (BOLD) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BOLD Bull vs. Bear Conversation Board — What's Your Call at $2.44?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BOLD 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $3.14 (+27.1%)
📌 Pinned Debate Forensic balance-sheet metrics (Altman Z 2.5, Debt/Equity 0.5) indicate the company is not in acute distress, and recent insider purcha
Forensic balance-sheet metrics (Altman Z 2.5, Debt/Equity 0.5) indicate the company is not in acute distress, and recent insider purchases were reported.. When you look under the hood at BOLD, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (10/20) has been quietly accumulating below $3.16. My 12M target is $3.14.
SectorRotator 🐂 BULL
@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH
🎯 Target: $2.03 (-17.8%)
Spot @ $2.47 The company reported negative operating income, net income, and free cash flow in every listed period, with ROIC at -35% and no reporte
Fading this rally in BOLD at $2.47. The company reported negative operating income, net income, and free cash flow in every listed period, with ROIC at -35% and no reported revenue.. With a beta of 1.0 and the stock sitting at $2.47 (52-wk range $0.96–$3.16), the easy multiple expansion is already priced in.